YH01
/ Beijing Yinmei Future Biomedical
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 02, 2025
A multicenter Phase I trial of YH01 injection for bladder infusion in patients with moderate to high-risk non-muscular invasive bladder cancer (NMIBC) who have failed to respond to BCG infusion therapy
(ChiCTR)
- P2 | N=9 | Not yet recruiting | Sponsor: The First Medical Center of the Chinese People's Liberation Army General Hospital; Beijing Yinmei Future Biomedical Technology Co., Ltd.
New P2 trial • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1